Scholars Central

PerspectivePublished 13 Jul 2016

Beyond Jadad: some essential features in trial quality

Authors: Sunny Y Alperson, Vance W Berger

Clinical Investigation

Volume 3 · Issue 12 · Pages 1119

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Randomized trials are considered the gold standard for design in medical research. However, poor quality trials often escape scrutiny cloaked under the umbrella term ‘randomized trials‘, leading to misinformation and bringing tangible harm to patients who rely on only valid research evidence. To enhance both trial quality and the quality of evidence, we need to recognize potential flaws that can invalidate entire trials. This perspective will discuss some key issues in clinical trials including a preservation, surrogate and composite end points and spin reporting. In addition, current quality rating scales and a reporting guide will be examined for their capacity to evaluate and guide trial quality on the features discussed. Finally, the quality evaluating tools will be summarized and a future perspective on trial quality provided.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Clinical Investigation.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Investigation
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Sunny Y Alperson”
  • BylineArticles whose byline prints “Vance W Berger”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels